Research and Development Expenses. Research and development expenses for the three-month period ended March 31, 2019, totaled $0 in comparison with $3,200, for the comparable quarter a year ago. The decrease of $3,600, or 100% is due to the completion of clinical activities associated with the erectile dysfunction trial and pre-clinical research on the Anmiostem stem cell. https://www.sec.gov/Archives/edgar/data/1187953/000114420419027322/tv521079_10q.htm
Research and development expenses for the year ended December 31, 2018, totaled $96,621 https://www.sec.gov/Archives/edgar/data/1187953/000114420419017462/tv516069_10k.htm